Altoida Company

Altoida Inc. provides health care professionals objective measurements of cognitive performance and is indicated for use as an adjunctive tool to aid in evaluation of perceptual and memory function in patients over 62+ years old. The Altoida iPad based application is the world’s first validated solutions to enter the market as a pre-symptomatic, computational biomarker to predict the risk of Alzheimer’s Disease. The Altoida "Neuro Motor Index" (NMI) application can detect early & subtle micro-errors (accuracy) and micro-movements (latency) during everyday function, up to 6 years prior to the onset of typical neurodegenerative symptoms, e.g. symptomatic Alzheimer's Disease". The Altoida NMI test does not identify the presence or absence of a clinical diagnosis and cannot be used as a stand-alone diagnostic tool and is therefore to be used only as configured by Altoida Inc. Altoida’s Medical Device “AMD” is an FDA class II medical device (510K exempt) and CE marked Class I medical device.
Technology: NeuroTech
Industry: Augmented Reality, Health Diagnostics, Medical Device, mHealth
Headquarters: Houston, Texas, United States
Founded Date: 2014-01-01
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 1
Last Funding Type: Seed

Visit Website
info@altoida.com
https://twitter.com/altoida
Register and Claim Ownership